Closed · RFA-IP-11-003 · CFDA 93.185 · Discretionary

Annual Estimates of Influenza Vaccine Effectiveness for Preventing Laboratory-Confirmed Influenza in the United States

Federal grant opportunity posted by Centers for Disease Control and Prevention - ERA, cataloged on Grants.gov.

up to $785K
Award range
Closed
Status
March 1, 2011
Close date
5
Expected awards

The verdict

Annual Estimates of Influenza Vaccine Effectiveness for Preventing Laboratory-Confirmed Influenza in the United States is a closed discretionary listing from Centers for Disease Control and Prevention - ERA that offered Up to $785,000 across 5 expected awards. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 639 other opportunities from Centers for Disease Control and Prevention - ERA.

up to $785K
award range
Closed
application status
5
expected awards
93.185
CFDA program

Archived opportunity record

Annual Estimates of Influenza Vaccine Effecti… is closed (last close March 1, 2011). Check the agency catalog for replacement NOFOs. Centers for Disease Control and Prevention - ERA still indexes 639 other opportunities here.

According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.

Deadline tracker

Application window closed

Closed March 1, 2011

Posted Jan 10 Closes Mar 1

Expected Awards

5

Instrument

Cooperative Agreement

Description

Influenza is an important cause of morbidity, mortality, and healthcare burden across all age groups. Because influenza viruses are constantly changing and vaccines are reformulated every year, annual estimates of the effectiveness of influenza vaccines in preventing influenza infection and its associated complications are needed in order to evaluate the protection provided by annual, nationwide vaccination programs. Estimating influenza vaccine effectiveness (VE) as soon as possible after the start of a seasonal influenza epidemic or pandemic and monitoring it over time will be essential in order to guide influenza vaccination and control policy. The populations to be studied will include those for whom CDC’s Advisory Committee on Immunization Practices recommends receipt of a licensed influenza vaccine. Influenza vaccination can prevent or reduce a number of outcomes, including laboratory-confirmed influenza virus infection, symptomatic illness given infection, severe illness and related complications due to influenza, the likelihood of transmitting the virus to others, or a combination of these. Thus, accurate estimation of vaccine effectiveness requires a multi-component approach, including accurate assessment of vaccination status, laboratory-confirmed disease outcomes, timing of illness and vaccination, and assessment of other factors that may affect vaccine use and immune response to vaccination. In addition, serological assessment of vaccine response and influenza antibody outcomes among vaccinated and unvaccinated individuals is also needed in order to understand vaccine response. Many additional factors can also affect the assessment of VE in observational studies such as the sensitivity and specificity of outcome measures, specimen collection methods, timing of vaccination, the setting for case and control recruitment, and the ratio of influenza illness to non-influenza respiratory illness. Moreover, a number of potential modifiers of vaccine response and vaccine effectiveness have been identified, including individual factors, environmental factors, and viral and infectious disease factors. Thus, applicants must describe plans to identify and control for a variety of potential confounders in each proposed analysis.

Catch-all / unrestricted eligibility mark · RFA-IP-11-003

Grants.gov marks Annual Estimates of Influenza Vaccine Effecti… with a catch-all / unrestricted eligibility code (Unrestricted / see official listing). Read the official announcement text for the real applicant filter — the code alone is not a door list. The extract does not mark applicant cost-sharing as required. Instrument: Cooperative Agreement. Funding-activity code maps to Health (HL). 54 other Centers for Disease Control and Prevention - ERA listings share this eligibility-code string (8% of 640).

Code 99
Unrestricted / see official listing

Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Agency Contact

Centers for Disease Control and Prevention (CDC) Procurement and Grants Office (PGO) Technical Information and Managment Section (TIMS) Phone 770-488-2700

What to do next

Annual Estimates of Influenza Vaccine Effecti… is closed; use the parent program and agency catalog for the next funding cycle.

  • Browse open federal opportunities in the same category when this listing is closed. Open opportunities
  • Look up CFDA 93.185 across all indexed listings before you commit to this opportunity alone. Eligibility finder
  • Compare award ranges across federal categories before you pick a single CFDA. All categories

Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Data sourced from the SAM.gov Assistance Listings and Grants.gov. See our methodology for details. Retrieved and formatted by PlainGrants